The purpose of this study is to evaluate the investigational drug, silmitasertib (a pill taken by mouth), in combination with FDA approved drugs for solid tumors. An investigational drug is one that has not been approved by the U.S. Food & Drug Administration (FDA), or any other regulatory authorities around the world for use alone or in combination with any drug, for the condition or illness it is being used to treat.
The goals of this part of the study are:
* Establish a recommended dose of silmitasertib in combination with chemotherapy
* Test the safety and tolerability of silmitasertib in combination with chemotherapy in subjects with cancer
* To determine the activity of study treatments chosen based on:
* How each subject responds to the study treatment
* How long a subject lives without their disease returning/progressing

Start Date30 Oct 2024

Sponsor / Collaborator

Hershey Medical Center

NCT06202521

/ TerminatedPhase 2

Evaluation of the Safety and Efficacy of Silmitasertib (CX-4945) in Combination With Standard of Care (SOC) for Treating Patients With Community-Acquired Pneumonia (CAP) Associated With SARS-CoV-2 and Influenza Viral Infections

This is a Phase II, multi-center, double-blind, randomized, interventional study in approximately 120 subjects to evaluate clinical benefit of CX-4945 in adult outpatients with SARS-CoV-2 and influenza viral infection-associated pneumonia. The subjects will be recruited into two domains, including SARS-CoV-2 and influenza virus domains. The study will compare the efficacy of Standard of Care (SOC) combined with CX-4945 against SOC paired with a placebo, utilizing a 1:1 allocation ratio in each domain.

Start Date20 Mar 2024

Sponsor / Collaborator

Senhwa Biosciences, Inc.

NCT05817708

/ CompletedPhase 1

A Dose Selection Phase 1 Study Evaluating the Safety and Tolerability of Silmitasertib

This is a Phase I single center, open-label, parallel design in 30 subjects to evaluate safety and tolerability of CX-4945 200mg QD, 200 mg BID and 400mg BID doses (10 subjects in each regimen) for continuously 5 days in healthy subjects for dose selection.

Start Date28 Nov 2022

Sponsor / Collaborator

Senhwa Biosciences, Inc.

100 Clinical Results associated with Silmitasertib

100 Translational Medicine associated with Silmitasertib

100 Patents (Medical) associated with Silmitasertib

307

Literatures (Medical) associated with Silmitasertib

01 Jun 2026·CNS Neuroscience & Therapeutics

X‐Linked USP11 Drives Depression‐Like Behaviors by Stabilizing CK2α and Disrupting Mitochondrial Function

Article

Author: Honghan Zhang ; Ningyuan Li ; Lingfeng Zhang ; Zhaowen Nie ; Yuqi Feng ; Yingyue Zhang ; Yuhui Zhang ; Hanchun Yan ; Wei Wang ; Ruiling Li ; Zhongchun Liu ; Hao Duan ; Xinhua Song ; Chao Wang ; Siqi Sun

ABSTRACT:

Aims:

To explore the role and mechanism of X‐linked USP11 in mitochondrial dysfunction associated with depression.

Methods:

USP11 knockout mice and USP11 overexpression mice in the prefrontal cortex were constructed, and the role of USP11 in mitochondrial dysfunction in depression was evaluated by behavioral tests and quantitative analysis of mitochondrial function changes in the prefrontal cortex. The interaction protein CK2α of USP11 in depression was identified by IP‐MS, and the role of CK2α was confirmed by using the selective inhibitor CX4945. The direct effects of USP11 and CK2α on mitochondrial function were further verified by using primary neurons.

Results:

USP11 mediates depression‐like behaviors and impairs mitochondrial function in mice. Mechanistically, USP11 binds to and deubiquitinates CK2α, stabilizing its protein level and promoting mitochondrial dysfunction. The selective inhibitor CX4945 reverses the impairment of neuronal mitochondrial function by CK2α.

Conclusion:

This study demonstrates that USP11 directly binds to and deubiquitinates CK2, affecting mitochondrial function in the mPFC and leading to depressive‐like behaviors in mice.

01 Apr 2026·LEUKEMIA

Enhancing tyrosine kinase inhibitor sensitivity by restoring IKAROS activity on GLUT1 expression and glycolysis in Philadelphia chromosome-positive acute lymphoblastic leukemia

Article

Author: Han, Qi ; Hanel, Walter G ; Zhang, Linyao ; Ge, Zheng ; Mims, Alice S ; Xiang, Huimin ; Brammer, Jonathan E ; Woyach, Jennifer A ; Eisfeld, Ann-Kathrin ; Song, Chunhua ; Lapalombella, Rosa

Abstract:

Many patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) are still less sensitive to tyrosine kinase inhibitors (TKIs). Ph+ ALL shows a high incidence of IKZF1 deletions. Casein kinase II (CK2)-mediated hyperphosphorylation of IKZF1 , encoding protein IKAROS, contributes to its dysfunction, and CK2 inhibitor, CX-4945, restores IKAROS function in high-risk ALL. Here, we found that Ph+ ALL cells with IKZF1 deletion are inherently resistant to TKIs. The combination of TKIs (imatinib or ponatinib) with CX-4945 significantly extended the survival and reduced the tumor burden in the IKZF1 deletion (Ik6 + ) Ph+ ALL patient-derived xenograft (PDX) mouse model; particularly, the patient died of relapse shortly after treatment with the third-generation TKI and the CD19/CD3 bispecific antibody blinatumomab. GLUT1 is highly expressed in the Ph+ ALL and associated with synergy of TKIs with CX-4945; Seahorse assay showed enhanced glycolysis in the patient sample with Ik6 + Ph+ ALL; GLUT1 knockdown suppresses glycolysis and induces apoptosis in the cells. The combination of TKIs with CX-4945 demonstrates the synergistic efficacy through restoring IKAROS transcriptional repression of GLUT1 and further suppressing glycolysis in Ph+ ALL. Our results identify new mechanisms underlying TKI sensitivity and novel approaches to overcome TKI resistance through transcriptional repression of the key genes in glycolysis in Ph+ ALL.

01 Apr 2026·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Inhibiting CK2 in breast cancer: From molecular targets to drug candidates

Review

Author: Al-Zoubi, Raed M ; Bani-Yaseen, Abdulilah D ; Agouni, Abdelali ; Al-Zoubi, Sally R ; Al-Qudimat, Ahmad R ; Khan, Abbas ; Hanbali, Basma ; Al Zoubi, Mazhar Salim ; Farhan, Ala'a ; Al Jabiry, Asia ; Shkoor, Mohanad

Casein kinase 2 (CK2) is a constitutively active serine/threonine kinase that orchestrates multiple oncogenic signaling networks, including PI3K/Akt, NF-κB, JAK/STAT3, Wnt/β-catenin, and DNA damage response pathways. Its broad involvement in cell survival, proliferation, and therapy resistance has positioned CK2 as a compelling target in oncology, particularly in breast cancer where CK2α and CK2β are frequently overexpressed and correlate with poor prognosis. Over the past decades, a wide range of CK2 inhibitors has been developed ranging from classical ATP-competitive scaffolds (TBB, DMAT, CX-4945) to highly selective second-generation chemical probes (SGC-CK2-1, AB668) and substrate-targeting peptides (CIGB-300). While two candidates, CX-4945 and CIGB-300, have advanced to clinical evaluation, major challenges persist, including limited selectivity, suboptimal pharmacokinetics, and reduced in vivo potency. Notably, kinome-wide profiling has revealed that several traditional inhibitors, including CX-4945, display substantial off-target activity, complicating the attribution of cellular phenotypes directly to CK2 inhibition. Emerging strategies including allosteric, αD-pocket-directed, bivalent, and substrate-targeting approaches have substantially improved selectivity and enabled more precise interrogation of CK2 biology. Preclinical evidence highlights strong antitumor effects of CK2 blockade in hormone-refractory and triple-negative breast cancer (TNBC), with additional potential to overcome endocrine and chemoresistance. This review integrates recent advances in CK2 biology, summarizes the evolution of CK2 inhibitor classes, and outlines the opportunities and remaining barriers for translating CK2 inhibition into effective cancer therapeutics.

News (Medical) associated with Silmitasertib

15 Jul 2026

·www.prnewswire.com

GEM and Senhwa Biosciences have formally executed a Share Purchase Agreement for up to NT$500 million

TAIPEI and SAN DIEGO, July 14, 2026 /PRNewswire/ -- GEM Global Yield LLC SCS ("GEM") has executed a Share Purchase Agreement (the "SPA") with the existing shareholders of Taiwan-listed Senhwa Biosciences Inc. (TPEx: 6492), under which GEM has committed up to NT$500 million (approximately US$15.5 million) to purchase shares in the Company over the next 3-5 years. Purchases under the SPA may occur from time to time at the election of certain shareholders, subject to the terms and conditions of the SPA. During the lifetime of the SPA, GEM will not, directly or indirectly, effect any short sale of Senhwa's shares. Taiwan's biotechnology industry continues to attract increasing international attention through innovative oncology research, expanding global clinical collaborations and the adoption of artificial intelligence to accelerate drug discovery and clinical development. Under the framework of the SPA, the equity commitment from GEM provides additional financial flexibility and is expected to support continued investment in Senhwa's clinical pipeline, potential in-licensing opportunities, and AI-enabled pipeline prioritization and expansion. The company's lead assets are CX-5461 (pidnarulex) and CX-4945 (silmitasertib), two investigational oncology therapies being studied across multiple cancer indications. Senhwa has established research and development collaborations with organizations including the U.S. National Cancer Institute (NCI), BeOne Medicines, and CellType, a Y Combinator-backed artificial intelligence company whose platform incorporates technology developed with Google DeepMind. "We are very pleased that a prominent international investment group like GEM recognizes Senhwa's long-term potential and has chosen to provide access to significant capital to Senhwa over the next few years," said Dr. Pin-Yen Huang, Acting Chief Executive Officer of Senhwa Biosciences. "GEM's validation strengthens our global market positioning as we continue to advance our oncology pipeline, expand strategic international collaborations, and bring innovative therapies to patients around the world." CX-5461 is currently involved in studies sponsored by the NCI and Senhwa expects to initiate a clinical study combining the drug with BeOne Medicines' PD-1 antibody, tislelizumab. CX-4945 is being investigated across several oncology indications, including cholangiocarcinoma, CNS tumors and pediatric cancers. In addition, preclinical studies are evaluating both compounds as potential combination partners for RAS-targeted therapies, although their clinical utility in this setting has not yet been established. From a regulatory standpoint, both candidates have secured orphan drug and rare pediatric disease designations from health authorities. For biotech investors, the pediatric designation is a key metric, as it preserves the company's eligibility to receive a marketable Priority Review Voucher (PRV) should the drugs eventually secure regulatory approval. About GEM GEM Global Yield LLC SCS ("GEM") is a $3.4 billion private equity and alternative investment group with offices in Paris, New York, and Nassau (Bahamas). GEM manages a diverse set of investment vehicles focused on emerging markets and has completed over 590 transactions in 70 countries. Its family of funds and investment vehicles provide GEM and its partners with exposure to small-mid cap management buyouts, private investments in public equities, and select venture investments. About Senhwa Biosciences Senhwa Biosciences Inc. is a Taiwan-based biotechnology company developing novel oncology therapeutics for cancers with significant unmet medical needs. Its pipeline includes CX-5461 and CX-4945, which are being evaluated across solid tumors and hematologic malignancy indications through international clinical and research collaborations. Forward-Looking Statements This release contains forward-looking statements regarding, among other things, anticipated financing, clinical development plans, regulatory milestones, strategic collaborations and the potential development of investigational drug candidates. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including risks related to clinical development, regulatory review, financing, commercialization and market conditions. Nothing contained herein should be construed as a guarantee of future clinical, regulatory or commercial outcomes. SOURCE Senhwa Biosciences, Inc 21% more press release views with Request a Demo

Orphan DrugLicense out/in

03 Mar 2026

·www.prnewswire.com

Senhwa Biosciences Signs Major Strategic MOU with Y Combinator-Backed AI Biotech Company CellType to Accelerate the Evolution of CX-4945 into Version 2.0 and Reshape the Global Immunotherapy Landscape

TAIPEI and SAN DIEGO, March 3, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage company focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced the signing of a major strategic Memorandum of Understanding (MOU) with CellType, an AI-driven biotech company backed by Y Combinator (Winter 2026). Under this partnership, the two companies will integrate CellType's proprietary AI platform to accelerate the clinical development and global commercialization strategy of Senhwa's core asset, Silmitasertib (CX-4945). Prior to formalizing the collaboration, the foundational research underlying CellType's technology was conducted at Yale University in collaboration with Google DeepMind, where researchers computationally predicted and experimentally validated a novel immune-modulatory mechanism of CX-4945. This strategic alliance marks a transformative milestone for Senhwa: CX-4945 is evolving from a single-target small molecule into a platform-enabling asset—"CX-4945 2.0." Through AI-driven deep data validation, Senhwa aims to expand potential indications, significantly enhance clinical success probability, and strengthen the asset's attractiveness for partnerships with international pharmaceutical companies for licensing discussion. In parallel, CellType will feature CX-4945 as the flagship case study of its AI platform, showcasing real-world validation results to global investors—demonstrating how AI can fundamentally transform traditional drug development models, reduce R&D risk, and amplify therapeutic value. Senhwa Chairman Benny T. Hu stated: "By integrating CellType's cutting-edge AI foundation models—capable of reasoning about biology at the cellular level, and rooted in pioneering research from Yale University and Google DeepMind—into Senhwa's clinical-stage core asset, we are not simply accelerating development—we are redefining the strategic positioning of CX-4945. This collaboration represents Senhwa's official entry into the next phase of AI-driven drug development. We highly recognize CellType's scientific excellence and global vision, and we look forward to unlocking new therapeutic possibilities for cancer patients worldwide while delivering sustainable, long-term structural value growth for our shareholders." AI-Driven Mechanistic Breakthrough CellType was founded by computational biologist Dr. David van Dijk. The company is backed by Y Combinator (Winter 2026). Its proprietary AI platform applies large language models to single-cell gene expression—the first of its kind—enabling sophisticated decoding of complex tumor microenvironment (TME) signaling. Through the original research collaboration with Google DeepMind at Yale University, researchers screened over 4,000 compounds and identified CX-4945 as a highly promising candidate. AI-predicted findings were subsequently validated in interdisciplinary laboratories at Yale University. Results indicate that beyond its known mechanism, CX-4945 demonstrates previously unrecognized immune-modulatory potential—including amplification of immune activation, enhancement of tumor antigen presentation, and conversion of "cold tumors" into "hot tumors." These properties may significantly improve immunotherapy efficacy and help overcome resistance challenges. Six-Month Pilot Program and Strategic Framework Under the MOU, the parties will initiate a six-month pilot program focused on: Indication expansion strategies, Biomarker discovery and validation, Combination therapy synergy evaluation in the context of immuno-oncology and new targets for treating different types of cancers and Establishment of an AI-driven translational validation framework. This collaboration not only position CX-4945 as a core immune-sensitizing molecule in immuno-oncology but also establishes Senhwa as CellType's founding strategic partner. The agreement preserves flexibility for deeper collaboration structures in the future, including joint ventures, co-development, or licensing arrangements. Market Opportunity and Strategic Outlook The global cancer immunotherapy market is entering a high-growth phase, with industry forecasts projecting the market to reach approximately US$305.8 billion by 2033. Despite rapid expansion, overcoming immunotherapy resistance and optimizing the tumor microenvironment remain among the most critical and value-defining challenges in oncology. This partnership extends beyond a technical pilot—it sends a clear signal to global capital markets: the valuation paradigm of CX-4945 is accelerating, and AI is emerging as a powerful multiplier of clinical success probability. Looking ahead, Senhwa and CellType will continue to deepen their collaboration, advancing CX-4945 from an innovative therapeutic candidate to a core AI-enabled immunotherapy platform asset—jointly redefining the next key inflection point in cancer immunotherapy and creating enduring value for shareholders, partners, and patients worldwide. SOURCE Senhwa Biosciences, Inc. 21% more press release views with Request a Demo

Immunotherapy

23 Dec 2025

·www.prnewswire.com

Senhwa Biosciences Highlights AI-Validated Oncology Platform and Strategic Clinical Collaborations Targeting Next-Generation Immuno-Oncology products at Its 2025 Annual Investor Conference

TAIPEI and SAN DIEGO, Dec. 23, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage companies focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today outlined continued progress across its AI-enabled drug development platform at its 2025 annual investor conference, reinforcing its strategic position as the global immuno-oncology landscape enters a period of generational transition. Global blockbuster immune-oncology products now face major patent expirations before 2030 pharmaceutical companies are either actively developing or acquiring next-generation assets that are highly combinable, scalable across multiple tumor types with potential of becoming treatment standard in different types of cancers. Senhwa is addressing this demand through an integrated strategy that combines artificial intelligence validation, precision clinical development, and global pharmaceutical partnerships. Recently, Google DeepMind applied its latest C2S-Scale biological AI model to analyze more than 4,000 drug candidates and identified Senhwa's lead compound Silmitasertib (CX-4945) as the most potential compound to revigorate immune system to combat with cancer. The study, supported by Google's computing infrastructure, DeepMind's proprietary AI models, and preclinical validation conducted by Yale University, demonstrated that CX-4945 significantly enhances tumor antigen presentation—an essential mechanism for improving immune recognition of cancer cells. This independent third-party validation highlights the potential of CX-4945 as an immune-sensitizing agent and represents a notable milestone in the application of AI to oncology drug discovery. By addressing the long-standing challenge of immunologically "cold" tumors, which had limited response to immunotherapy, CX-4945 has a unique position in the rapidly expanding field of cold-to-hot tumor conversion. In parallel, Senhwa continues to advance its clinical pipeline through strategic international collaboration. The company recently announced a clinical collaboration with BeOne Medicines to evaluate Senhwa's lead candidate, Pidnarulex (CX-5461), in combination with BeOne's commercially approved, best-in-class PD-1 inhibitor tislelizumab. The initial focus of the collaboration includes pancreatic cancer and advanced solid tumors, including immunotherapy-resistant melanoma. CX-5461 is a first-in-class small molecule with a differentiated dual mechanism of action that stabilizes DNA G-quadruplex (G4) structures while inhibiting RNA polymerase I (Pol I). This dual activity induces replication stress in tumor cells and activates the innate immune cGAS–STING pathway, effectively converting immune-cold tumors into immune-active environments. Robust preclinical data supports the application of CX-5461 in enhancing the efficacy of existing immunotherapies and becoming the ideal candidate for combination therapy with immune-oncology products. Senhwa believes this pathway-level, multi-target strategic approach positions CX-5461 as a potential next-generation treatment back bone in cancers where immunotherapy is used, rather than positioning the compound as a single-asset or indication-specific solution. This strategic positioning has attracted interest from global pharmaceutical companies seeking high value added platform assets, as reflected by ongoing and prior collaborations involving leading multinational partners. Looking ahead, Senhwa expects multiple value-driving catalysts over the next one to three years, including clinical data readouts for CX-5461 and CX-4945, expansion of global partnerships, potential licensing collaborations, and increased visibility at major international medical conferences such as ASCO, AACR, and ESMO. "Senhwa has transitioned beyond early-stage discovery and development into a company building a scalable, AI-validated oncology platform," said the Company. "At a pivotal moment for immuno-oncology, we are focused on advancing differentiated science with the potential to create long-term value for patients, partners, and shareholders." SOURCE Senhwa Biosciences, Inc. 21% more press release views with Request a Demo

Immunotherapy

100 Deals associated with Silmitasertib

External Link

KEGG	Wiki	ATC	Drug Bank
-	Silmitasertib	-	DB15408

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Ewing Sarcoma	Phase 2	United States	Senhwa Biosciences, Inc.	06 Nov 2024
Liposarcoma	Phase 2	United States	Senhwa Biosciences, Inc.	06 Nov 2024
Relapsed Solid Neoplasm	Phase 2	United States	Senhwa Biosciences, Inc.	06 Nov 2024
Rhabdomyosarcoma	Phase 2	United States	Senhwa Biosciences, Inc.	06 Nov 2024
Haemophilus influenzae pneumonia	Phase 2	Taiwan Province	Senhwa Biosciences, Inc.	20 Mar 2024
Influenza A virus infection	Phase 2	Taiwan Province	Senhwa Biosciences, Inc.	20 Mar 2024
Community Acquired Pneumonia	Phase 2	Taiwan Province	Senhwa Biosciences, Inc.	20 Mar 2024
COVID-19	Phase 2	United States	Senhwa Biosciences, Inc.	30 Nov 2020
Recurrent Medulloblastoma	Phase 2	United States	Senhwa Biosciences, Inc.	25 Jul 2019
Intrahepatic Cholangiocarcinoma	Phase 2	United States	Senhwa Biosciences, Inc.	01 Jun 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06202521 (CTgov)	Phase 2	Influenza A virus infection \| COVID-19 \| Haemophilus influenzae pneumonia ... View more	45	Placebo (SARS-CoV-2 domain) (SARS-CoV-2 domain: Placebo + SOC)	qzbfxnvmxs = dwbygkwbil ypciwesyuz (btpffyubtj, cvnyfcwxyp - rxxcfzwftq) View more	-	08 Jan 2026
				Placebo (Influenza virus domain) (Influenza virus domain: Placebo + SOC)	qzbfxnvmxs = kymvjjxsvy ypciwesyuz (btpffyubtj, xctsskluot - rglcteqwle) View more
NCT03897036 (CTgov)	Phase 1	Basal Cell Nevus Syndrome \| Basal Cell Carcinoma \| Metastatic basal cell carcinoma	25	CX-4945 (Treatment-Duration-Increment)	lctnmtzzks = qqqrwitowj zfxxviuivx (lndehralxa, dryjgnksim - osfzchqtod) View more	-	20 May 2025
				CX-4945 (Expansion)	cewtlnxqsf(ektgeylswc) = zpklrxdzrh vjpvuxaryn (gepqkmkong, xcsboswpbh - qisprkghfv) View more
NCT05817708 (CTgov)	Phase 1	COVID-19	30	CX-4945 (CX-4945 200mg QD)	cvwygqsina = dvtjhulnyp yqlqkrormu (kygfezeffo, rrdukxqukq - dwtjmfegtc) View more	-	27 Jan 2025
				CX-4945 (CX-4945 200mg BID)	cvwygqsina = uuvnsusgii yqlqkrormu (kygfezeffo, ivtdvcbuzx - jfsixgrbis) View more
NCT04663737 (CTgov)	Phase 2	COVID-19	20	Silmitasertib (Group A)	ybmavlydim = dxoudgsvbs desbylhgkb (tqubehhmca, oetxlpeqzv - uddotqiypm) View more	-	16 Dec 2024
				SOC (Group B)	ybmavlydim = bnkffklkwm desbylhgkb (tqubehhmca, tgbjkzhyug - jifialwiui) View more
NCT02128282 (S4-13-001, Pubmed) Manual	Phase 1/2	Bile Duct Neoplasms First line	84	Gemcitabine+Cisplatin+Silmitasertib	tmxsdjlmje(ckonerxysq) = ptmgdoviuw elfsaqqgzj (mvbbaxxfve, 7.6 - 14.7) View more	Positive	24 Sep 2022
				Gemcitabine+Cisplatin	tmxsdjlmje(ckonerxysq) = lzqvvmalcf elfsaqqgzj (mvbbaxxfve, 3.1 - NE) View more
NCT04663737 (Biospace) Manual	Phase 2	COVID-19	20	CX-4945	jhiqpgoiel(jwfhechwrh) = voyopzopxj wgvlqabggk (gqliebgqdc ) View more	Positive	20 Oct 2021
				Standard of Care	xdkcnddonu(gkgapeihwm) = uxruzewsnp cpypuamrdc (zbkajldhyy ) View more
NCT02128282 (S4-13-001, ASCO_GI 12021 \| ASCO_GI 22021) Manual	Phase 1/2	Metastatic Cholangiocarcinoma First line	87	gemcitabine+cisplatin+Silmitasertib	jruuouccje(wrdbiratcq) = rlkxqdyydd modtjtofbg (yfgkawccvp, 7.6 - 14.7) View more	Positive	22 Jan 2021
NCT02128282 (ASCO_GI2017)	Phase 1/2	Advanced biliary tract cancer	127	CX-4945	mvesggdrby(myfcvsrwvv) = kyejxyxeer uwxlcfivkj (usysdpyvif ) View more	-	21 Mar 2017

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis